Oncolytics Biotech Inc. (ONCY)
NASDAQ: ONCY · Real-Time Price · USD
0.6080
+0.0311 (5.39%)
At close: Jun 13, 2025, 4:00 PM
0.6099
+0.0019 (0.31%)
After-hours: Jun 13, 2025, 7:59 PM EDT
Oncolytics Biotech Stock Forecast
Stock Price Forecast
According to 3 professional analysts, the 12-month price target for Oncolytics Biotech stock ranges from a low of $3.00 to a high of $5.00. The average analyst price target of $4.33 forecasts a 612.17% increase in the stock price over the next year.
Price Target: $4.33 (+612.17%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Oncolytics Biotech stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 2 | 2 | 2 | 2 |
| Buy | 1 | 1 | 2 | 2 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 4 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $5 | Strong Buy | Reiterates | $5 | +722.37% | May 21, 2025 |
| Jones Trading | Jones Trading | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | May 16, 2025 |
| Maxim Group | Maxim Group | Strong Buy Maintains $5 → $3 | Strong Buy | Maintains | $5 → $3 | +393.42% | Mar 10, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $5 | Strong Buy | Reiterates | $5 | +722.37% | Mar 10, 2025 |
| RBC Capital | RBC Capital | Buy Maintains $6 → $5 | Buy | Maintains | $6 → $5 | +722.37% | Mar 10, 2025 |
Financial Forecast
Revenue This Year
n/a
from 441.76M
Revenue Next Year
n/a
EPS This Year
-0.40
from -0.41
EPS Next Year
-0.42
from -0.40
Financial currency is CAD. Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | 6.3M | 109.4M | ||
| Avg | n/a | 1.2M | 26.3M | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | 8,927.2% | ||
| Avg | - | - | 2,070.9% | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.36 | -0.38 | -0.13 | ||
| Avg | -0.40 | -0.42 | -0.34 | ||
| Low | -0.46 | -0.48 | -0.45 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.